BriaCell Therapeutics Corp. (NASDAQ:BCTXW) Short Interest Down 22.5% in December

BriaCell Therapeutics Corp. (NASDAQ:BCTXW) was the target of a large decline in short interest in the month of December. As of December 15th, there was short interest totaling 3,266 shares, a decline of 22.5% from the November 30th total of 4,215 shares. Based on an average daily trading volume, of 17,915 shares, the short-interest ratio is currently 0.2 days. Based on an average daily trading volume, of 17,915 shares, the short-interest ratio is currently 0.2 days.

BriaCell Therapeutics Trading Up 1.0%

BCTXW opened at $0.05 on Tuesday. The company’s 50-day moving average price is $0.05 and its 200 day moving average price is $0.05. BriaCell Therapeutics has a fifty-two week low of $0.01 and a fifty-two week high of $0.43.

BriaCell Therapeutics Company Profile

BriaCell Therapeutics Corp is a clinical-stage biotechnology company focused on the development of novel immunotherapeutic treatments for breast cancer and other solid tumors. The company’s research strategy centers on harnessing the body’s immune system to recognize and attack cancer cells, with an emphasis on off-the-shelf allogeneic platforms that can be readily administered without the need for patient-specific manufacturing.

The company’s lead candidate, Bria-IMT, is derived from a human breast tumor cell line engineered to express immune-stimulatory molecules designed to trigger both innate and adaptive anti-tumor responses.